Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such...
JUST FINISHED TRADE, GOOD TRADE...!!!
It looks like this stock is ready to spike. On 6/10/2020, NK said its NK cells appear to be resistant even to acute hypoxia and are capable of maintaining tumor killing activity in conditions comparable with a suppressive tumor microenvironment. Long DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information...
After hitting 100SMA, it went down and seems that found its support which worked several times before. It may attract the buyers again 12 months Consensus Price Target: $94.21 if you find my charts useful, please leave me "like" or "comment". Please don't trade according to the ideas, rely on your own knowledge. Thx
Concave describes an inward curve; its opposite, convex, describes a curve that bulges outward. They are used to describe gentle, subtle curves, like the kinds found in mirrors or lenses. A graph is said to be concave up at a point if the tangent line to the graph at that point lies below the graph in the vicinity of the point and concave down at a point if the...
Monthly cup and handle, looks nice. Thanks to yamgaexpress for pointing this out..
$MRK bullish divergence with RSI at 0.61 fibonacci retracement. Merck & Co Inc (MRK) is scheduled to announce its earnings on Wednesday, February 5 before market opens. Daily chart.
Ascending Scallop, this is a bearish reversal pattern.
We keep seeing Clinical Stage Companies that are publicly traded, with new FDA Approvals, and the stocks are blasting off. Many of those are trading over $100 with no revenue, profits or earnings. Here Merck is, sitting under $100, beating earnings, with record revenue and profit, and paying an almost 3.00% dividend....It is simply outrageous. Wall Street...
Hi, today we are going to talk about Merck & Co. and its current landscape. Merck & Co. shares are in evidence today as was unveiled that the company it's going to acquire ArQule for $20 per share in cash, totalizing a deal of $2.7 billion. In this season of Mergers and Acquisitions, the Merck & Co. move is based on its interest in pushing its already established...
Keep it Simple! Looking at MRK on the Daily there has been an easy setup for a short entry at the 87 range (Orange box). The frequent wicks into this range suggest that there are being fills made for short positions. I have set three profit targets (Green boxes) for this trade, where I will almost completely out of the trade by the third profit target. The trade...
MKR at pivot resistance level. Might breakout unless BTC do it first and dump alts.
Hey everyone, Moving away from the typical crypto posts today. We are checking out MRK. This stock has seen some hefty losses in the past few days, pushing the RSI into a oversold area The increasing bear volume has not been supportive, and the price is breaking past the .382 fib level. The stock is looking to find support, but the last few days have not...
MRK is approaching our first support at 66.70 (horizontal overlap support, 100% fibonacci extension, 50% fiboancci retracement) where a strong bounce might occur above this level pushing price up to our major resistance at 74.94 (50% fibonacci retracment, 61.8% fiboancci extension). Stochastic (21,5,3) is also approaching support where we might see a...
Why is this setup good? Strong contextual uptrend Price continues moving in the direction of main trend since it bounced at support EMA(100) and EMA(50) Momentum building on MACD 12-26, MACD signal line crossed the 0 line First reaction (contraction) since MACD crossover Trigger Candle testing EMA 3, 6 and 18 Low Setup Risk - just 1.29% in risk ...
Head and shoulder pattern, right shoulder looking like it is currently in formation. Currenly prices are right at previous resistance and support. If 76.38 is bounced from, short target is at the next level of support at 72.78 RSI and Stoch indicate market is strongly over bought, which further point toward a short play being the case over the next few days.